Pretreatment and Posttreatment Evolution of NfL Levels in ICANS (2024)

Key Points

Question How early are elevations in plasma neurofilament light chain (NfL) levels observed before the development of neurotoxicity after chimeric antigen receptor T-cell therapy?

Findings In this cross-sectional study of 30 patients undergoing cellular therapy, NfL levels were elevated in patients who developed immune effector cell–associated neurotoxicity syndrome (ICANS) at baseline (preinfusion) and remained elevated for 30 days.

Meaning Preinfusion NfL elevations suggest ICANS may unmask preexisting neurologic injury present prior to infusion, suggesting that early screening is feasible before drug administration and that inclusion of preexisting neurologic injury may be considered in ICANS pathophysiology models traditionally focusing on the interaction of inflammation and endothelial dysfunction.

Importance Determining whether neurofilament light chain (NfL) elevations in patients who develop immune effector cell–associated neurotoxicity syndrome (ICANS) occur before or after infusion of cellular product is important to identify high-risk patients and inform whether neuroaxonal injury is latent or a consequence of treatment.

Objective To quantify serial NfL levels in patients undergoing cellular therapy.

Design, Setting, and Participants This retrospective 2-center study examined plasma NfL levels in 30 patients with detailed medical and treatment history, including all major pretreatment and posttreatment risk factors. Exclusion criteria included dementia and severe, symptomatic central nervous system (CNS) involvement.

Main Outcomes and Measures Patients’ NfL levels were measured at 7 time points: baseline (prelymphodepletion), during lymphodepletion, postinfusion day (D) 1, D3, D7, D14, and D30. Prediction accuracy for the development of ICANS was next modeled using receiver operating characteristic (ROC) classification. Finally, univariate and multivariate modeling examined the association between NfL levels, ICANS, and potential risk factors including demographic (age, sex), oncologic (tumor burden, history of CNS involvement), neurologic (history of nononcologic CNS disease or neuropathy), and neurotoxic exposure histories (vincristine, cytarabine, methotrexate, or CNS radiotherapy).

Results A total of 30 patients (median [range] age, 64 [22-80] years; 12 women [40%] and 18 men [60%]) were included. Individuals who developed ICANS had elevations in NfL prior to lymphodepletion and chimeric antigen receptor T-cell infusion compared with those who did not develop ICANS (no ICANS: 29.4 pg/mL, vs any ICANS: 87.6 pg/mL; P < .001). Baseline NfL levels further predicted ICANS development with high accuracy (area under the ROC curve, 0.96), sensitivity (0.91), and specificity (0.95). Levels of NfL remained elevated across all time points, up to 30 days postinfusion. Baseline NfL levels correlated with ICANS severity but not demographic factors, oncologic history, nononcologic neurologic history, or history of exposure to neurotoxic therapies.

Conclusions and Relevance In a subset of patients in this cross-sectional study, the risk of developing ICANS was associated with preexisting neuroaxonal injury that was quantifiable with plasma NfL level. This latent neuroaxonal injury was present prior to drug administration but was not associated with historic neurotoxic therapies or nononcologic neurologic disease. Preinfusion NfL may further permit early screening and identification of patients most at risk for ICANS. Additional studies are needed to determine NfL’s utility as a predictive biomarker for early (preemptive or prophylactic) intervention and to delineate the origin of this underlying neural injury.

After chimeric antigen receptor (CAR) T-cell therapy, 40% to 60% of patients will develop neurotoxicity termed immune effector cell–associated neurotoxicity syndrome (ICANS).^1-3 While the number of patients treated with cellular therapy (<10 000 annually) represents a small fraction of all patients treated for cancer, the indications for cellular therapy are rapidly growing. Symptom onset is typically 3 to 9 days postinfusion and range from encephalopathy to aphasia to cerebral edema.^2,3 While most cases of low-grade (grade 1-2) ICANS are self-limited, grade 3 or higher ICANS can cause substantial morbidity and mortality.⁴ The early identification of patients at risk for ICANS is critical for preemptive management. Recently, neurofilament light chain (NfL), an axonal structural protein with elevated levels in multiple neurodegenerative and neuroinflammatory diseases,⁵ has emerged as a potential biomarker in ICANS.^6,7 Schoeberl and colleagues⁷ reported postinfusion NfL elevations up to 5 days prior to peak ICANS. However, it remains unclear if this is an acute postinfusion elevation or a chronic change predating cellular therapy. Likewise, NfL’s association with established ICANS risk factors (preinfusion baseline tumor burden, CAR T-cell dose, history of preexisting neurologic comorbidities,⁸ and postinfusion ferritin level, lactate dehydrogenase (LDH) level, platelet count, fibrinogen level, and C-reactive protein [CRP] level^3,8-11) is unclear. In this study, we investigate serial plasma NfL levels in patients undergoing cellular therapy, starting from before lymphodepletion to 30 days postinfusion, and examine its association with ICANS and potential risk factors.

Thirty patients treated with a CD19 CAR T-cell therapy at Washington University in Saint Louis (WU) and Case Western Reserve (CW) were evaluated. Patients at WU were participants from the Center for Gene and Cellular Immunotherapy registry (July 1, 2019, to December 31, 2020), and patients at CW were enrolled in a phase 1 trial with locally manufactured CAR T cells.¹² Cohort size was limited to all available samples that met inclusion and exclusion criteria (eMethods in the Supplement). The American Society for Transplantation and Cellular Therapy criteria defined ICANS and cytokine release syndrome (CRS) grading.⁴ Each site’s respective institutional review board approved the study, and written consent was obtained as part of the aforementioned study and trial.

Neurofilament light chain level was assayed using a Simoa HD-X kit (Quanterix) from archived samples. Time points included baseline (before lymphodepletion), lymphodepletion (preinfusion), day 1 (D1), D3, D7, D14, and D30. Laboratory correlates, including platelet count and CRP, LDH, fibrinogen, and ferritin levels, were quantified in each site’s clinical laboratory for available time points (lymphodepletion, D1, D3, D5, and D7).

Wilcoxon rank-sum tests evaluated univariate comparisons between ICANS grade 1 or higher vs grade 0, and ICANS grade 3 or higher vs grade 0 to 2. False discovery rate corrected for multiple comparisons. Each biomarker then served as a predictor in a binomial logistic regression model for ICANS status. The regression model probability estimates defined a receiver operating characteristic (ROC) curve. The area under the ROC curve (AUC) and optimal operating point of a given ROC curve then determined model accuracy, with validation on 10 000 random permutations of 24 of the 30 patients.

Point biserial correlation compared NfL level with categorical covariates (sex, history of CNS involvement, nononcologic CNS disease, neuropathy, or vincristine, cytarabine, high-dose methotrexate, intrathecal methotrexate, or CNS radiotherapy exposure). Rank-correlation compared continuous (NfL, CRP, LDH, fibrinogen, and ferritin levels, platelet count, age, tumor burden) and ordinal (ICANS grade, CRS grade) variables. The absolute value of the resulting cross-correlation matrix subserved agglomerative hierarchical clustering. Multivariate modeling included data-driven (Lasso regression) and a priori–defined (partial correlation) approaches to model ICANS grade (the outcome variable; eMethods in the Supplement). All analyses were performed using Matlab, version R2020a (Mathworks).

We examined baseline (prelymphodepletion) NfL levels in 30 individuals (median [range] age, 64 [22-80] years; 12 women [40%] and 18 men [60%]; 23 [77%] with a history of diffuse large B-cell lymphoma) treated with CD19 CAR T cells (63% axicabtagene ciloleucel; Table 1). Patients who developed any grade ICANS, low-grade (grade 1-2) ICANS, and grade 3 or higher ICANS had significant elevations in baseline NfL level (mean, 87.6 pg/mL, 115.3 pg/mL, and 71.7 pg/mL, respectively) compared with the grade 0 group (29.4 pg/mL; Figure, A). The grade 1 to 2 and grade 3 or higher subgroups did not differ from one another.

Baseline NfL accurately predicted ICANS development (AUC, 0.96; sensitivity, 0.91; specificity, 0.95; Figure, B), surpassing postinfusion markers across all time points (eFigure 1 in the Supplement). Likewise, hierarchical clustering grouped ICANS grade with NfL (eFigures 2 and 3 in the Supplement). Comparable results were observed for NfL between grade 3 or higher ICANS and the combined grade 0 to 2 ICANS cohort (AUC, 0.86; sensitivity, 1.0; specificity, 0.82; eFigures 4 and 5 in the Supplement).

Baseline NfL level correlated with ICANS grade (r = 0.74; P < .001). No association was observed with demographic, oncologic, neurologic, or exposure to neurotoxic risk factors, including CRS (Figure, C). Multivariate modeling likewise identified NfL level as the main contributing factor to ICANS grade (eFigure 6 and eResults in the Supplement). Finally, NfL levels remained elevated in individuals who developed ICANS for 30 days after infusion (Figure, D) with persistent correlation with ICANS severity across all time points (eFigure 7 in the Supplement). The classification accuracy of NfL persisted across available time points, despite smaller group sizes (Table 2).

ICANS remains an enigmatic neurologic syndrome whose pathophysiology remains poorly understood. A need remains to identify patients most at risk prior to onset given the high morbidity/mortality and potential for rapid clinical decline. Here, we show that preinfusion plasma NfL levels were a robust marker for ICANS development. The association between NfL level and ICANS grade persisted independent of potential confounds, including age, sex, tumor burden, history of neurologic disease, and history of neurotoxic therapies. Plasma NfL levels also remained elevated after infusion for up to 30 days after infusion.

Critically, this study demonstrates that NfL elevations are present prior to drug administration in a cohort of patients treated with CD19-directed cellular therapy. Preliminary work suggested NfL elevations may be observed 5 days prior to peak ICANS,⁷ but it was unknown if this reflected an acute change after drug infusion or chronic elevations that predate lymphodepletion and infusion.

While unlikely to be the sole driver of ICANS, neural injury reflected by NfL may aid in identifying a high-risk subset of patients undergoing cellular therapy. However, NfL’s association with current models of ICANS pathophysiology remains unclear. Current models center on systemic inflammatory changes leading to endothelial dysfunction, blood-brain barrier breakdown,⁸ and systemic cytokine and/or monocytes infiltration into the CNS, resulting in neuroinflammation and symptoms.^8,9,11 These models underappreciate predisposing risk factors for ICANS development, such as neurologic injury.⁸ Whether this injury reflects a subclinical neuroinflammatory process or a microvascular process affecting axon health remains unclear.¹³ Given that known endothelial and blood-brain barrier dysfunction is associated with ICANS,⁸ the latter is more plausible.

The source of injury remains unknown, with no clear association with exposure to neurotoxic therapy, though this may reflect low power. ICANS has been associated with acute white matter (WM) microvascular and macrovascular injury on imaging, including hemorrhagic and nonhemorrhagic encephalitis and strokes.¹⁴ Incidentally, NfL elevations are also associated with WM lesions and neuroinflammatory and vascular insults such as stroke, encephalitis, and lesion burden in multiple sclerosis.^5,13,15 Together this suggests possible subclinical WM injury through microvascular injury via an as of yet uncharacterized pathway. Persistent 30-day postinfusion elevations suggest that while the acute, symptomatic phase of ICANS may resolve, persistent occult neurologic injury persists. Finally, correlation with a systemic process like CRS would be unusual given NfL’s neuroaxonal origin. Indeed, no correlation was observed between NfL level and CRS in the current cohort, despite significant association between CRS and ICANS (r = 0.49; P = .006; eResults in the Supplement).

Study limitations include a cohort treated predominantly with axicabtagene ciloleucel, insufficient power for subgroup comparisons between ICANS grades, and a lack of available cerebrospinal fluid samples or imaging to provide additional information about the underlying pathophysiology.

In this cross-sectional study, the risk of developing ICANS was associated with preexisting neuroaxonal injury that was quantifiable with plasma NfL level in a subset of patients. This latent neuroaxonal injury was present prior to drug administration but was not associated with historic neurotoxic therapies or nononcologic neurologic disease. Additional studies are needed to examine preinfusion NfL elevations as a biomarker for prophylaxis or early intervention in patients at risk for ICANS.

Accepted for Publication: June 9, 2022.

Published Online: September 1, 2022. doi:10.1001/jamaoncol.2022.3738

Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2022 Butt OH et al. JAMA Oncology.

Corresponding Author: Omar H. Butt, MD, PhD, Department of Medicine - Division of Oncology, Campus Box 8056, 660 S Euclid Ave, St Louis, MO 63110 (omarhbutt@wustl.edu).

Author Contributions: Dr Butt had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Drs Ghobadi and Ances were senior authors and contributed equally to this work.

Concept and design: Butt, Zhou, Campian, DiPersio, Ghobadi, Ances.

Acquisition, analysis, or interpretation of data: Butt, Zhou, Caimi, Luckett, Wisch, Derenoncourt, Lee, Wu, de Lima, Campian, Frank, DiPersio, Ghobadi.

Drafting of the manuscript: Butt, Zhou, Luckett, Derenoncourt, Ghobadi, Ances.

Critical revision of the manuscript for important intellectual content: Butt, Zhou, Caimi, Wisch, Lee, Wu, de Lima, Campian, Frank, DiPersio, Ghobadi, Ances.

Statistical analysis: Butt, Zhou, Luckett, Wisch, Ghobadi.

Obtained funding: Butt, DiPersio, Ghobadi, Ances.

Administrative, technical, or material support: Derenoncourt, Wu, de Lima, Campian, Frank, DiPersio.

Supervision: Zhou, Campian, DiPersio, Ghobadi, Ances.

Conflict of Interest Disclosures: Drs Butt, DiPersio, Ghobadi, and Ances reported a provisional patent on the use of plasma NfL as a predictive biomarker for ICANS pending (application No. 63/084,667). Dr Caimi reported personal fees (advisory board) from Kite Pharma, Novartis, ADC Therapeutics, Genmab, Takeda, Lilly, and Bristol Myers Squibb and personal fees (research funding and advisory board) from Genentech outside the submitted work. Dr de Lima reported serving on advisory boards for Bristol Myers Squibb and Pfizer outside the submitted work. Dr Campian reported grants (research funding) from NeoImmuneTech and support for investigator-initiated clinical trials from Incyte, Merck, and Ipsen outside the submitted work. Dr DiPersio reported equity (cofounder) from Magenta Therapeutics and Wugen Therapeutics outside the submitted work. No other disclosures were reported.

Funding/Support: This work was made possible due to by the generous support of the McDonnell Center for Systems Neuroscience at Washington University in St Louis (New Research Proposal), Washington University in St Louis (22-3922-26239A), Institute of Clinical and Translational Sciences (Clinical and Translational Research Funding Program), Washington University in St Louis (P18-03173-17), the Paula and Rodger O. Riney Fund, the Daniel J. Brennan MD Fund, and the Fred Simmons and Olga Mohan Fund, National Institutes of Health/National Cancer Institute: R35 CA210084 NCI Outstanding Investigator Award (Dr DiPeriso), RG-1802-30253 National Multiple Sclerosis Society (Dr Wu), and R01NS106289 National Institute of Neurological Disorders and Stroke (Dr Wu).

Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Additional Contributions: We thank all participants at Siteman Cancer Center and Case Comprehensive Cancer Center for their role in the sample provision and data collection.